[⁶⁸Ga]PSMA-11 for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer

References

• Bowden GD, Scott PJH, Boros E. Radiochemistry: a hot field with opportunities for cool chemistry. ACS Cent Sci. 2023;9(12):2183–2195. doi: 10.1021/acscentsci.3c01050
   PubMed Web of Science ®Google Scholar
• Barrio M, Fendler WP, Czernin J, et al. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer. Expert Rev Mol Diagn. 2016;16(11):1177–1188. doi: 10.1080/14737159.2016.1243057
   PubMed Web of Science ®Google Scholar
• Beierwaltes WH. Indication and contraindications for treatment of thyroid cancer with radioactive iodine. Ann Intern Med. 1952;37(1):23–30.
   PubMed Web of Science ®Google Scholar
• Rufini V, Shulkin B. The evolution in the use of MIBG in more than 25 years of experimental and clinical applications. Q J Nucl Med Mol Imaging. 2008;52(4):341–350.
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96(4):1259–1266. doi: 10.1182/blood.V96.4.1259
   PubMed Web of Science ®Google Scholar
• Langbein T, Weber WA, Eiber M. Future of theranostics: an outlook on precision oncology in nuclear medicine. J Nucl Med. 2019;60(Supplement 2):13S–19S. doi: 10.2967/jnumed.118.220566
   PubMedGoogle Scholar
• Tourinho-Barbosa R, Srougi V, Nunes-Silva I, et al. Biochemical recurrence after radical prostatectomy: what does it mean? Int Braz J Urol. 2018;44(1):14–21. doi: 10.1590/s1677-5538.ibju.2016.0656
   PubMed Web of Science ®Google Scholar
• Antonov P, Raycheva G, Popov V. Unexpected long-term survival in an adult patient with metastatic prostate cancer. Urol Case Rep. 2021;37:101634. doi: 10.1016/j.eucr.2021.101634
   PubMed Web of Science ®Google Scholar
• Gebrael G, Sayegh N, Tripathi N, et al. Impact of initial timing of metastatic disease on survival in patients with newly diagnosed metastatic castration-resistant prostate cancer treated with androgen receptor pathway inhibitors. Urol Pract. 2024;11(1):32–35. doi: 10.1097/UPJ.0000000000000471
   PubMed Web of Science ®Google Scholar
• Batra A, Glick D, Valdes M. Contemporary systemic therapy intensification for prostate cancer: a review for General practitioners in oncology. Curr Oncol. 2024;31(2):1047–1062. doi: 10.3390/curroncol31020078
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Lin P, Tombal B, et al. Five-year survival prediction and safety outcomes with enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer from the PREVAIL trial. Eur Urol. 2020;78(3):347–357. doi: 10.1016/j.eururo.2020.04.061
   PubMed Web of Science ®Google Scholar
• O’Dwyer E, Bodei L, Morris MJ. The role of theranostics in prostate cancer. Semin Radiat Oncol. 2021;31(1):71–82. doi: 10.1016/j.semradonc.2020.07.004
   PubMed Web of Science ®Google Scholar
• Zhang H, Koumna S, Pouliot F, et al. PSMA theranostics: current landscape and future outlook. Cancers (Basel). 2021;13(16):4023. doi: 10.3390/cancers13164023
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2017;67(1):7–30. doi: 10.3322/caac.21387
   PubMed Web of Science ®Google Scholar
• Sabbagh A, Mohamad O, Lichter KE, et al. Management of patients with recurrent and metachronous oligometastatic prostate cancer in the era of PSMA PET. Cancers (Basel). 2022;14(24):6194. doi: 10.3390/cancers14246194
   PubMed Web of Science ®Google Scholar
• Roberts MJ, Maurer T, Perera M, et al. Using PSMA imaging for prognostication in localized and advanced prostate cancer. Nat Rev Urol. 2023;20(1):23–47. doi: 10.1038/s41585-022-00670-6
   PubMedGoogle Scholar
• Dorff TB, Fanti S, Farolfi A, et al. The evolving role of prostate-specific membrane antigen–based diagnostics and therapeutics in prostate cancer. Am Soc Clin Oncol Educ Book. 2019;39(39):321–330. doi: 10.1200/EDBK_239187
   PubMedGoogle Scholar
• Lauri C, Chiurchioni L, Russo VM, et al. PSMA expression in solid tumors beyond the prostate gland: ready for theranostic applications? J Clin Med. 2022;11(21):6590. doi: 10.3390/jcm11216590
   PubMed Web of Science ®Google Scholar
• Pellegrino S, Fonti R. A look into the future: the role of PSMA beyond prostate cancer. Eur J Nucl Med Mol Imaging. 2023;51(1):278–280. doi: 10.1007/s00259-023-06388-w
   PubMed Web of Science ®Google Scholar
• Rizzo A, Dall’armellina S, Pizzuto DA, et al. PSMA radioligand uptake as a biomarker of neoangiogenesis in solid tumours: diagnostic or theragnostic factor? Cancers (Basel). 2022;14(16):4039. doi: 10.3390/cancers14164039
   PubMed Web of Science ®Google Scholar
• Capasso G, Stefanucci A, Tolomeo A. A systematic review on the current status of PSMA-targeted imaging and radioligand therapy. Eur J Med Chem. 2024;263:115966. doi: 10.1016/j.ejmech.2023.115966
   PubMed Web of Science ®Google Scholar
• Rizvi T, Deng C, Rehm PK. Indium-111 capromab pendetide (ProstaScint(®)) demonstrates renal cell carcinoma and aortocaval nodal metastases from prostate adenocarcinoma. World J Nucl Med. 2015;14(3):209–211. doi: 10.4103/1450-1147.163259
   PubMedGoogle Scholar
• Rosar F, Schaefer-Schuler A, Bartholomä M, et al. [89Zr]Zr-PSMA-617 PET/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimates. Eur J Nucl Med Mol Imaging. 2022;49(13):4736–4747. doi: 10.1007/s00259-022-05925-3
   PubMed Web of Science ®Google Scholar
• Eppard E, de la Fuente A, Benešová M, et al. Clinical translation and first in-human use of [44Sc]Sc-PSMA-617 for PET imaging of metastasized castrate-resistant prostate cancer. Theranostics. 2017;7(18):4359–4369. doi: 10.7150/thno.20586
   PubMed Web of Science ®Google Scholar
• Dos Santos JC, Schäfer M, Bauder-Wüst U, et al. Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy? Eur J Nucl Med Mol Imaging. 2019;46(5):1081–1091. doi: 10.1007/s00259-018-4220-z
   PubMed Web of Science ®Google Scholar
• Chakravarty R, Lan X, Chakraborty S, et al. Astatine-211 for PSMA-targeted α-radiation therapy of micrometastatic prostate cancer: a sustainable approach towards precision oncology. Eur J Nucl Med Mol Imaging. 2023;50(7):1844–1847. doi: 10.1007/s00259-023-06178-4
   PubMed Web of Science ®Google Scholar
• Ling SW, de Blois E, Hooijman E, et al. Advances in 177Lu-PSMA and 225Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer. Pharmaceutics. 2022;14(10):2166. doi: 10.3390/pharmaceutics14102166
   PubMed Web of Science ®Google Scholar
• Rathke H, Flechsig P, Mier W, et al. Dosimetry estimate and initial clinical experience with 90Y-PSMA-617. J Nucl Med. 2019;60(6):806–811. doi: 10.2967/jnumed.118.218917
   PubMed Web of Science ®Google Scholar
• Parent EE, Savir-Baruch B, Gayed IW, et al. 177Lu-PSMA therapy. J Nucl Med Tech. 2022;50(3):205–212. doi: 10.2967/jnmt.122.263814
   PubMed Web of Science ®Google Scholar
• Sathekge M, Knoesen O, Meckel M, et al. 213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44(6):1099–1100. doi: 10.1007/s00259-017-3657-9
   PubMed Web of Science ®Google Scholar
• Siefert R, Alberts IL, Afshar-Oromeih A, et al. Prostate cancer theranostics: PSMA targeted therapy. PET Clin. 2021;16(3):391–396. doi: 10.1016/j.cpet.2021.03.004
   PubMed Web of Science ®Google Scholar
• Rodnick ME, Sollert C, Stark D, et al. Cyclotron-based production of 68Ga, [68Ga]GaCl₃, and [68Ga]Ga-PSMA-11 from a liquid target. EJNMMI Radiopharm Chem. 2020;5(1):25. doi: 10.1186/s41181-020-00106-9
   PubMedGoogle Scholar
• Hillier SM, Maresca KP, Femia FJ, et al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 2009;69(17):6932–6940. doi: 10.1158/0008-5472.CAN-09-1682
   PubMed Web of Science ®Google Scholar
• Wirtz M, Schmidt A, Schottelius M, et al. Synthesis and in vitro and in vivo evaluation of urea-based PSMA inhibitors with increased lipophilicity. EJNMMI Res. 2018;8(1):84. doi: 10.1186/s13550-018-0440-2
   PubMedGoogle Scholar
• Eder M, Schäfer M, Bauder-Wüst U, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23(4):688–397. doi: 10.1021/bc200279b
   PubMed Web of Science ®Google Scholar
• Afshar-Oromeih A, Haberkorn U, Eder M, et al. [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging. 2012;39(6):1085–1086. doi: 10.1007/s00259-012-2069-0
   PubMed Web of Science ®Google Scholar
• Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56(5):668–674. doi: 10.2967/jnumed.115.154153
   PubMed Web of Science ®Google Scholar
• Abghari-Gerst M, Armstrong WR, Nguyen K, et al. A comprehensive assessment of 68Ga-PSMA-11 PET in biochemically recurrent prostate cancer: results from a prospective multi-center study in 2005 patients. J Nucl Med. 2022;63(4):567–572. doi: 10.2967/jnumed.121.262412
   PubMed Web of Science ®Google Scholar
• Fendler WP, Eiber M, Beheshti M, et al. 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44(6):1014–1024. doi: 10.1007/s00259-017-3670-z
   PubMed Web of Science ®Google Scholar
• Fendler WP, Eiber M, Beheshti M, et al. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50(5):1466–1486. doi: 10.1007/s00259-022-06089-w
   PubMed Web of Science ®Google Scholar
• Houshmand S, Lawhn-Heath C, Behr S. PSMA PET imaging in the diagnosis and management of prostate cancer. Abdom Radiol (NY). 2023;48(12):3610–3623. doi: 10.1007/s00261-023-04002-z
   PubMed Web of Science ®Google Scholar
• Belal SL, Frantz S, Minarik D, et al. Applications of artificial intelligence in PSMA PET/CT for prostate cancer imaging. Sem Nucl Med. 2024;54(1):141–149. doi: 10.1053/j.semnuclmed.2023.06.001
   PubMed Web of Science ®Google Scholar
• Chow KM, So WZ, Lee HJ, et al. Head-to-head comparison of the diagnostic accuracy of prostate-specific membrane antigen positron emission tomography and conventional imaging modalities for initial staging of intermediate- to high-risk prostate cancer: a systematic review and meta-analysis. Eur Urol. 2023;84(1):36–48. doi: 10.1016/j.eururo.2023.03.001
   PubMed Web of Science ®Google Scholar
• Uemura M, Watabe T, Hoshi S, et al. The current status of prostate cancer treatment and PSMA theranostics. Ther Adv Med Oncol. 2023;15:17588359231182293. doi: 10.1177/17588359231182293
   Web of Science ®Google Scholar
• Huang S, Ong S, D M, et al. Comparison of 18F-based PSMA radiotracers with [68Ga]Ga-PSMA-11 in PET/CT imaging of prostate cancer – a systematic review and met-analysis. Prostate Cancer Prostatic Dis. 2023. doi: 10.1038/s41391-023-00755-2
   Google Scholar
• García Garzón JR, de Arcocha Torres M, Delgado-Bolton R, et al. 68Ga-PSMA PET/CT in prostate cancer. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2018;37(2):130–138. doi: 10.1016/j.remnie.2017.10.016
   PubMed Web of Science ®Google Scholar
• Adnan A, Basu S. PSMA receptor-based PET-CT: the basics and current status in clinical and research applications. Diagnostics (Basel). 2023;13(1):158. doi: 10.3390/diagnostics13010158
   PubMedGoogle Scholar
• Terroir M, Lamesa C, Krim M. RadioLigand therapy with [177Lu]Lu-PSMA-617 for salivary gland cancers: literature review and first compassionate use in france. Pharmaceuticals (Basel). 2023;16(5):754. doi: 10.3390/ph16050754
   PubMedGoogle Scholar
• Lepareur N. Cold kit labeling: the future of 68Ga radiopharmaceuticals. Sec Nucl Med. 2022;9:812050. doi: 10.3389/fmed.2022.812050
   Google Scholar
• Tan BF, Tan WCC, Wang FQ, et al. PSMA PET imaging and therapy in adenoid cystic carcinoma and other salivary gland cancers: a systematic review. Cancers (Basel). 2022;14(15):3585. doi: 10.3390/cancers14153585
   PubMed Web of Science ®Google Scholar
• Brunello S, Salvarese N, Carpanese D, et al. A review on the current state and future perspectives of [99mTc]Tc-housed PSMA-i in prostate cancer. Molecules. 2022;27(9):2617. doi: 10.3390/molecules27092617
   PubMed Web of Science ®Google Scholar
• Debnath S, Zhou N, McLaughlin M, et al. PSMA-targeting imaging and theranostic agents – current status and future perspective. Int J Mol Sci. 2022;23(3):1158. doi: 10.3390/ijms23031158
   PubMed Web of Science ®Google Scholar
• Manafi-Farid R, Ranjbar S, Araghi ZJ, et al. Molecular imaging in primary staging of prostate cancer patients: current aspects and future trends. Cancers (Basel). 2021;13(21):5360. doi: 10.3390/cancers13215360
   PubMed Web of Science ®Google Scholar
• Hennrich U, Eder M. [68Ga]Ga-PSMA-11: the first FDA-approved 68Ga-radiopharmaceutical for PET imaging of prostate cancer. Pharmaceuticals (Basel). 2021;14(8):713. doi: 10.3390/ph14080713
   PubMedGoogle Scholar
• Perera M, Papa N, Roberts M, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol. 2020;77(4):403–417. doi: 10.1016/j.eururo.2019.01.049
   PubMed Web of Science ®Google Scholar
• Mirzaei S, Lipp RW. Peptide and pseudo-peptide. Q J Nucl Med Mol Imaging. 2020;64(4):364–370. doi: 10.23736/S1824-4785.20.03311-7
   PubMed Web of Science ®Google Scholar
• Werner RA, Derlin T, Lapa C, et al. 18F-Labeled, PSMA-targeted radiotracers: leveraging the advantages of radiofluorination for prostate cancer molecular imaging. Theranostics. 2020;10(1):1–16. doi: 10.7150/thno.37894
   PubMed Web of Science ®Google Scholar
• Inubushi M, Miura H, Kuji I, et al. Current status of radioligand therapy and positron-emission tomography with prostate-specific membrane antigen. Ann Nucl Med. 2020;34(12):879–883. doi: 10.1007/s12149-020-01549-5
   PubMed Web of Science ®Google Scholar
• Bolzati C, Duatti A. The emerging value of 64Cu for molecular imaging and therapy. Q J Nucl Med Mol Imaging. 2020;64(4):329–337. doi: 10.23736/S1824-4785.20.03292-6
   PubMed Web of Science ®Google Scholar
• Hope TA, Goodman JZ, Allen IE, et al. Metaanalysis of 68Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology. J Nucl Med. 2019;60(6):786–793. doi: 10.2967/jnumed.118.219501
   PubMed Web of Science ®Google Scholar
• Ceci F, Castellucci P, Fanti S. Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer. Q J Nucl Med Mol Imaging. 2019;63(1):7–18. doi: 10.23736/S1824-4785.18.03059-5
   PubMed Web of Science ®Google Scholar
• Parghane R, Basu S. Small cell transformation of metastatic prostate adenocarcinoma diagnosed by dual-tracer PET/CT (68Ga-PSMA and 18F-FDG): potential clinical utility in therapeutic decision making and treatment monitoring. J Nucl Med Technol. 2019;47(1):85–87. doi: 10.2967/jnmt.118.215582
   PubMed Web of Science ®Google Scholar
• Virgolini I, Decristoforo C, Haug A, et al. Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45(3):471–495. doi: 10.1007/s00259-017-3882-2
   PubMed Web of Science ®Google Scholar
• Lenzo NP, Meyrick D, Turner JH. Review of gallium-68 PSMA PET/CT imaging in the management of prostate cancer. Diagnostics (Basel). 2018;8(1):16. doi: 10.3390/diagnostics8010016
   PubMedGoogle Scholar
• Giovacchini G, Giovannini E, Riondato M, et al. Radiopharmaceuticals for the diagnosis and therapy of neuroendocrine differentiated prostate cancer. Curr Radiopharm. 2017;10(1):6–15. doi: 10.2174/1874471009666161229123126
   PubMedGoogle Scholar
• Ceci F, Castellucci P, Cerci JJ, et al. New aspects of molecular imaging in prostate cancer. Methods. 2017;130:36–41. doi: 10.1016/j.ymeth.2017.07.009
   PubMed Web of Science ®Google Scholar
• Velikyan I. 68Ga-Based radiopharmaceuticals: production and application relationship. Molecules. 2015;20(7):12913–12943. doi: 10.3390/molecules200712913
   PubMed Web of Science ®Google Scholar
• Culter CS, Minoshima S. Shortage of Germanium-68/Gallium-68 Generations for the Production of Gallium 68. [Internet]. [cited 2024 Mar 7] Available from: https://s3.amazonaws.com/rdcms-snmmi/files/production/public/Ga68%20shortage%20letter.pdf
   Google Scholar
• Gallium (68Ga) chloride (accelerator produced) solution for radiolabeling. Eur Pharmacopoeia. 2020;10(10.3):4864–4865.
   Google Scholar
• Rodnick ME, Sollert C, Stark D, et al. Synthesis of 68Ga-radiopharmaceuticals using both generator-derived and cyclotron-produced 68Ga as exemplified by [68Ga]Ga-PSMA-11 for prostate cancer PET imaging. Nat Prot. 2022;17(4):980–1003. doi: 10.1038/s41596-021-00662-7
   PubMed Web of Science ®Google Scholar
• Svedjehed J, Pärnaste M, Gagnon K. Demystifying solid targets: simple and rapid distribution-scale production of [68Ga]GaCl3 and [68Ga]Ga-PSMA-11. Nucl Med Biol. 2022;104–105:1–10. doi: 10.1016/j.nucmedbio.2021.10.002
   PubMed Web of Science ®Google Scholar
• International Atomic Energy Agency. Gallium-68 Cyclotron Production. IAEA-TECDOC-1863. Vienna: IAEA; 2019.
   Google Scholar
• Wang IE, Brooks AF, Clark M, et al. Improved purification of cyclotron [68Ga]GaCl3 for the production of 68Ga radiopharmaceuticals. Nucl Med Biol. 2024;130-131:108892. doi: 10.1016/j.nucmedbio.2024.108892
   PubMed Web of Science ®Google Scholar
• Schweinsberg C, Johayem A, Llamazares A, et al. The first curie-quantity production of [68Ga]Ga-PSMA-HBED-CC. J Label Compd Radiopharm. 2019;62(S1):121.
   Google Scholar
• Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform [Internet]. [cited 2024 Mar 7]. Available from: https://www.prnewswire.com/news-releases/telix-to-acquire-artms-inc-and-its-advanced-isotope-production-platform-302079103.html
   Google Scholar
• UCLA Nuclear Medicine, Highlights of Prescribing Information Gallium Ga 68 PSMA-11 Injection, for intravenous use. [Internet]. [cited 2024 Mar 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212642s000lbl.pdf
   Google Scholar
• UCSF Nuclear Medicine. Highlights of prescribing information gallium Ga 68 PSMA-11 injection, for intravenous use. [Internet]. [cited 2024 Mar 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212643s000lbl.pdf
   Google Scholar
• Carlucci G, Ippisch R, Slavik R, et al. 68Ga-PSMA-11 NDA approval: A novel and successful academic partnership. J Nucl Med. 2021;62(2):149–155.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration, SNMMI. FDA Approves Pluvicto/Locametz for Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2022;63(5):13N.
   Web of Science ®Google Scholar
• Novartis pharmaceuticals corporation, LOCAMETZ® (kit for the preparation of gallium Ga 68 gozetotide injection), for intravenous use. [Internet]. [cited 2024 Mar 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215841s000lbl.pdf
   Google Scholar
• Telix Pharmaceuticals (US). ILLUCIX® (kit for the preparation of gallium Ga 68 gozetotide injection), for intravenous use. [Internet]. [cited 2024 Mar 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214032s001lbl.pdf
   Google Scholar
• Beyer T, Czernin J, Freudenberg L, et al. A 2022 international survey on the status of prostate cancer theranostics. J Nucl Med. 2023;64(1):47–53. doi: 10.2967/jnumed.122.264298
   PubMed Web of Science ®Google Scholar
• Sonni I, Pra AD, Dp O, et al. 68Ga-PSMA PET/CT-based atlas for prostate bed recurrence after radical prostatectomy: clinical implications for salvage radiation therapy contouring guidelines. J Nucl Med. 2023;64(6):902–909. doi: 10.2967/jnumed.122.265025
   PubMed Web of Science ®Google Scholar
• Jadvar H, Calais J, Fanti S, et al. Appropriate use criteria for prostate-specific membrane antigen PET imaging. J Nucl Med. 2022;63(1):59–68. doi: 10.2967/jnumed.121.263262
   PubMed Web of Science ®Google Scholar
• Ceci F, Oprea-Lager DE, Emmett L, et al. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur J Nucl Med Mol Imaging. 2021;48(5):1626–1638. doi: 10.1007/s00259-021-05245-y
   PubMed Web of Science ®Google Scholar
• Schaeffer EM, Srinivas S, Adra N, et al. NCCN guidelines insights: prostate cancer. J Natl Compr Canc Netw. 2022;20(12):1288–1298. doi: 10.6004/jnccn.2022.0063
   PubMed Web of Science ®Google Scholar
• Vorster M, Warwick J, Lawal IO, et al. South African guidelines for receptor radioligand therapy (RLT) with Lu-177-PSMA in prostate cancer. S Afr J Surg. 2019;57(4):45–51. doi: 10.17159/2078-5151/2019/v57n4a3107
   PubMed Web of Science ®Google Scholar
• Shen K, Liu B, Zhou X, et al. The evolving role of 18F-FDG PET/CT in diagnosis and prognosis prediction in progressive prostate cancer. Front Oncol. 2021;11:683793. doi: 10.3389/fonc.2021.683793
   PubMed Web of Science ®Google Scholar
• Sutherland DEK, Azad AA, Murphy DG, et al. Role of FDG PET/CT in management of patients with prostate cancer. Semin Nucl Med. 2024;54(1):4–13. doi: 10.1053/j.semnuclmed.2023.06.005
   PubMed Web of Science ®Google Scholar
• Chen R, Wang Y, Zhu Y, et al. The added value of 18F-FDG PET/CT compared with 68Ga-PSMA PET/CT in patients with castration-resistant prostate cancer. J Nucl Med. 2022;63(1):69–75. doi: 10.2967/jnumed.120.262250
   PubMed Web of Science ®Google Scholar
• Rosar F, Burgard C, David S, et al. Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT. Sci Rep. 2024;14(1):11271. doi: 10.1038/s41598-024-61961-z
   PubMed Web of Science ®Google Scholar
• Michalski K, Ruf J, Goetz C, et al. Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy. Eur J Nucl Med Mol Imaging. 2021;48(6):2024–2030. doi: 10.1007/s00259-020-05160-8
   PubMed Web of Science ®Google Scholar
• Wu Q, Bates A, Guntur P, et al. Detection rate of PSMA PET using different ligands in men with biochemical recurrent prostate cancer following radical treatment: a systematic review and meta-analysis of prospective studies. Acad Radiol. 2023. doi: 10.1016/j.acra.2023.08.044
   Web of Science ®Google Scholar
• Paymani Z, Rohringer T, Vali R, et al. Diagnostic performance of [18F]Fluorocholine and [68Ga]Ga-PSMA PET/CT in prostate cancer: a comparative study. J Clin Med. 2020;9(7):2308. doi: 10.3390/jcm9072308
   PubMed Web of Science ®Google Scholar
• Morigi JJ, Stricker PD, van Leeuwen PJ, et al. Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015;56(8):1185–1190. doi: 10.2967/jnumed.115.160382
   PubMed Web of Science ®Google Scholar
• Afshar-Oromeih A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(1):11–20. doi: 10.1007/s00259-013-2525-5
   PubMed Web of Science ®Google Scholar
• Olivier P, Giraudet AL, Skanjeti A, et al. Phase III Study of 18F-PSMA-1007 Versus 18F-Fluorocholine PET/CT for Localization of Prostate Cancer Biochemical Recurrence: A Prospective, Randomized, Crossover Multicenter Study. J Nucl Med. 2023;64(4):579–585. doi: 10.2967/jnumed.122.264743
   PubMed Web of Science ®Google Scholar
• Yadav D, Hwang H, Qiao W, et al. 18F-Fluciclovine versus PSMA PET imaging in primary tumor detection during Initial stating of high-risk prostate cancer: a systematic review and meta-analysis. Radiol Imag Cancer. 2022;4(2). doi: 10.1148/rycan.210091
   PubMedGoogle Scholar
• Calais J, Ceci F, Eiber M, et al. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. The Lancet Oncol. 2019;20(9):1286–1294. doi: 10.1016/S1470-2045(19)30415-2
   PubMed Web of Science ®Google Scholar
• Zhao G, Ji B. Heat-To-Head Comparison of 68Ga-PSMA-11 PET/CT and 99mTc-MDP Bone Scintigraphy for the Detection of Bone Metastases in Patients With Prostate Cancer: A Meta-Analysis. AJR Am J Roentgenol. 2022;219(3):386–395. doi: 10.2214/AJR.21.27323
   PubMed Web of Science ®Google Scholar
• Ljungberg M, Celler A, Konijnenberg MW, et al. MIRD pamphlet No. 26: joint EANM/MIRD guidelines for quantitative 177Lu SPECT applied for dosimetry of radiopharmaceutical therapy. J Nucl Med. 2016;57(1):151–162. doi: 10.2967/jnumed.115.159012
   PubMed Web of Science ®Google Scholar
• Pathmanandavel S, Crumbaker M, Ho B, et al. Evaluation of 177Lu-PSMA-617 SPECT/CT quantitation as a response biomarker within a prospective 177Lu-PSMA-617 and NOX66 combination trial (LuPIN). J Nucl Med. 2023;64(2):221–226. doi: 10.2967/jnumed.122.264398
   PubMed Web of Science ®Google Scholar
• Emmett L, John N, Pathmanandavel S, et al. Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT). Ther Adv Med Oncol. 2023;15:17588359231156392. doi: 10.1177/17588359231156392
   Web of Science ®Google Scholar
• Jackson PA, Hofman MS, Hicks RJ, et al. Radiation dosimetry in 177Lu-PSMA-617 therapy using a single posttreatment SPECT/CT scan: a novel methodology to generate time- and tissue-specific dose factors. J Nucl Med. 2020;61(7):1030–1036. doi: 10.2967/jnumed.119.233411
   PubMed Web of Science ®Google Scholar
• Danieli R, Stella M, Leube J, et al. Quantitative 177Lu SPECT/CT imaging for personalized dosimetry using a ring-shaped CZT-based camera. EJNMMI Phys. 2023;10(1):64. doi: 10.1186/s40658-023-00586-z
   PubMed Web of Science ®Google Scholar
• Peterson A, Wilderman S, Wong KK, et al. Monte Carlo bone marrow dosimetry in radioligand therapy using patient-specific marrow and lesion localization from quantitative 99mTc-sulfur colloid and 177Lu-PSMA-617 SPECT/CT. J Nucl Med. 2023;64(Suppl. 1):162. doi: 10.2967/jnumed.122.265338
   Google Scholar
• Chen G, Lu Z, Jiang H, et al. Lu-177-PSMA dosimetry for kidneys and tumors based on SPECT images at two imaging time points. Front Med (Lausanne). 2023;10:1246881. doi: 10.3389/fmed.2023.1246881
   PubMed Web of Science ®Google Scholar
• Resch S, Takayama Fouladgar S, Zacherl M, et al. Investigation of image-based lesion and kidney dosimetry protocols for 177Lu-PSMA-I&T therapy with and without a late SPECT/CT acquisition. EJNMMI Phys. 2023;10(1):11. doi: 10.1186/s40658-023-00529-8
   PubMed Web of Science ®Google Scholar
• Meyer C, Szidonya L, Winters C, et al. Quantitative imaging for 177Lu-PSMA treatment response monitoring and dosimetry. Front Nucl Med. 2023;3:1291253. doi: 10.3389/fnume.2023.1291253
   Google Scholar
• Clinical trials using gallium Ga 68 gozetotide. National Cancer Institute. [Internet]. 2023 [cited 2024 Jul 14]. Available from: https://www.cancer.gov/research/participate/clinical-trials/intervention/gallium-ga-68-gozetotide
   Google Scholar
• Peters SMB, Hofferber R, Privé BM, et al. [68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment. Eur J Nucl Med Mol Imaging. 2022;49(4):1101–1112. doi: 10.1007/s00259-021-05538-2
   PubMed Web of Science ®Google Scholar
• Hope TA, Eiber M, Armstrong WR, et al. Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective Phase 3 imaging trial. JAMA Oncol. 2021;7(11):1635–1642. doi: 10.1001/jamaoncol.2021.3771
   PubMed Web of Science ®Google Scholar
• Djaïleb L, Armstrong WR, Thompson D, et al. Presurgical 68Ga-PSMA-11 positron emission tomography for biochemical recurrence risk assessment: a follow-up analysis of a multicenter prospective Phase 3 imaging trial. Eur Urol. 2023;84(6):588–596. doi: 10.1016/j.eururo.2023.06.022
   PubMed Web of Science ®Google Scholar
• Burgard C, Hoffmann MA, Frei M, et al. Detection efficacy of 68Ga-PSMA-11 PET/CT in biochemical recurrence of prostate cancer with very Low PSA Levels: A 7-year, two-center “real-world”. Exper Cancers (Basel). 2023;15(5):1376. doi: 10.3390/cancers15051376
   PubMed Web of Science ®Google Scholar
• Ferdinandus J, Fendler WP, Farolfi A, et al. PSMA PET validates higher rates of metastatic disease for european association of urology biochemical recurrence risk groups: an international multicenter study. J Nucl Med. 2022;63(1):76–80. doi: 10.2967/jnumed.121.262821
   PubMed Web of Science ®Google Scholar
• Cornford P, Tilki D, van den Bergh RCN, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Arnhem The Netherlands: European Association of Urology Guidelines Office; 2024.
   Google Scholar
• Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024;In press. doi: 10.1016/j.eururo.2024.03.027
   Google Scholar
• Tilki D, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. part II-2024 ipdate: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2024;In press. doi: 10.1016/j.eururo.2024.04.010
   Google Scholar
• Fendler WP, Calais J, Eiber M, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol. 2019;5(6):856–863. doi: 10.1001/jamaoncol.2019.0096
   PubMed Web of Science ®Google Scholar
• Emmett L, Tang R, Nandurkar R, et al. 3-Year freedom from progression after 68Ga-PSMA PET/CT-triaged management in men with biochemical recurrence after radical prostatectomy: results of a prospective multicenter trial. J Nucl Med. 2020;61(6):866–872. doi: 10.2967/jnumed.119.235028
   PubMed Web of Science ®Google Scholar
• Calais J, Czernin J, Fendler WP, et al. Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]. BMC Cancer. 2019;19(1):18. doi: 10.1186/s12885-018-5200-1
   PubMedGoogle Scholar
• Buteau JP, Moon D, Fahey MT, et al. Clinical trial protocol for PRIMARY2: A multicentre, Phase 3, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 positron emission tomography/computed tomography in men with negative or equivocal multiparametric magnetic resonance imaging for the diagnosis of clinically significant prostate cancer. Eur Urol Oncol. 2023;S2588-9311(23):00253–5.
   Google Scholar
• Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091–1103. doi: 10.1056/NEJMoa2107322
   PubMed Web of Science ®Google Scholar
• Kratochwil C, Giesel FL, Stefanova M, et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617. J Nucl Med. 2016;57(8):1170–1176. doi: 10.2967/jnumed.115.171397
   PubMed Web of Science ®Google Scholar
• Hennrich U, Eder M. [177Lu]Lu-PSMA-617 (PluvictoTM): the first FDA-approved radiotherapeutical for treatment of prostate cancer. Pharmaceuticals (Basel). 2022;15(10):1292. doi: 10.3390/ph15101292
   PubMedGoogle Scholar
• Fallah J, Agrawal S, Gittleman H, et al. FDA approval summary: lutetium lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2023;29(9):1651–1657. doi: 10.1158/1078-0432.CCR-22-2875
   PubMed Web of Science ®Google Scholar
• Sathekge M, Bruchertseifer F, Knoesen O, et al. 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2019;46(1):129–138. doi: 10.1007/s00259-018-4167-0
   PubMed Web of Science ®Google Scholar
• Kratochwil C, Bruchertseifer F, Giesel FL, et al. 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57(12):1941–1944. doi:10.2967/jnumed.116.178673
   PubMed Web of Science ®Google Scholar
• Sathekge MM, Lawal IO, Bal C, et al. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study. Lancet Oncol. 2024;25(2):175–183. doi: 10.1016/S1470-2045(23)00638-1
   PubMed Web of Science ®Google Scholar
• Eisazadeh R, Mirshahvalad SA, Schwieghofer-Zwink G, et al. Pre-treatment 68 Ga-PSMA-11 PET/CT Prognostic Value in Predicting Response to 177Lu-PSMA-I&T Therapy and Patient Survival. Mol Imag Biol Ahead of Print. 2024;26(2):360–369. doi: 10.1007/s11307-024-01900-6
   PubMed Web of Science ®Google Scholar
• Hofman MS, Emmett L, Sandhu S, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797–804. doi: 10.1016/S0140-6736(21)00237-3
   PubMed Web of Science ®Google Scholar
• Hofman MS, Emmett L, Sandhu S, et al. Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncol. 2024;25(1):99–107. doi: 10.1016/S1470-2045(23)00529-6
   PubMed Web of Science ®Google Scholar
• Crumbaker M, Pathmanandavel S, Yam AO, et al. Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN). Eur Urol Oncol. 2021;4(6):963–970. doi: 10.1016/j.euo.2020.07.002
   PubMed Web of Science ®Google Scholar
• Emmett L, Subramaniam S, Joshua AM, et al. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). BJU Int. 2021;128(5):642–651. doi: 10.1111/bju.15491
   PubMed Web of Science ®Google Scholar
• Emmett L, Subramaniam S, Crumbaker M, et al. [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2024;25(5):563–571. doi: 10.1016/S1470-2045(24)00135-9
   PubMed Web of Science ®Google Scholar
• Emmett L, Subramaniam S, Zhang AY, et al. ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). J Clin Oncol. 2021;39(6 Suppl):TPS177–TPS177. doi: 10.1200/JCO.2021.39.6_suppl.TPS177
   Web of Science ®Google Scholar
• van Boxtel W, Lütje S, van Engen-van Grunsven ICH, et al. 68Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study. Theranostics. 2020;10(5):2273–2283. doi: 10.7150/thno.38501
   PubMed Web of Science ®Google Scholar
• Pathmanathan S, Tariq A, Pearce A, et al. Clinical impact of prostate-specific membrane antigen positron emission tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management. Eur J Nucl Med Mol Imaging. 2023;51(1):295–303. doi: 10.1007/s00259-023-06380-4
   PubMed Web of Science ®Google Scholar
• Bradshaw TJ, Boellaard R, Dutta J, et al. Nuclear medicine and artificial intelligence: best practices for algorithm development. J Nucl Med. 2022;63(4):500–510. doi: 10.2967/jnumed.121.262567
   PubMed Web of Science ®Google Scholar
• Chervenkov L, Sirakov N, Kostov G, et al. Future of prostate imaging: artificial intelligence in assessing prostatic magnetic resonance imaging. World J Radiol. 2023;15(5):136–145. doi: 10.4329/wjr.v15.i5.136
   PubMed Web of Science ®Google Scholar
• Zhau Y, Gafita A, Tetteh G, et al. Deep neural network for automatic characterization of lesion on 68Ga-PSMA PET/CT images. Annu Int Conf IEEE Eng Med Biol Soc. 2019;2019:951–954.
   PubMedGoogle Scholar
• Capobianco N, Sibille L, Chantadisai M, et al. Whole-body uptake classification and prostate cancer staging in 68Ga-PSMA-11 PET/CT using dual-tracer learning. Eur J Nucl Med Mol Imaging. 2022;49(2):517–526. doi: 10.1007/s00259-021-05473-2
   PubMed Web of Science ®Google Scholar
• Jafari E, Zarei A, Dadgar H, et al. A convolutional neural network–based system for fully automatic segmentation of whole-body [68Ga]Ga-PSMA PET images in prostate cancer. Eur J Nucl Med Mol Imaging. ahead pf print. 2023;51(5):1476–1487. doi: 10.1007/s00259-023-06555-z
   PubMed Web of Science ®Google Scholar
• Huang B, Yang Q, Li X, et al. Deep learning-based whole-body characterization of prostate cancer lesions on [68Ga]Ga-PSMA-11 PET/CT in patients with post prostatectomy recurrence. Eur J Nucl Med Mol Imaging. 2024;51(4):1173–1184. doi: 10.1007/s00259-023-06551-3
   PubMed Web of Science ®Google Scholar
• Erle A, Moazemi S, Lütje S, et al. Evaluating a machine learning tool for the classification of pathological uptake in whole-body PSMA-PET-CT scans. Tomography. 2021;7(3):301–312. doi: 10.3390/tomography7030027
   PubMed Web of Science ®Google Scholar
• Moazemi S, Khurshid Z, Erle A, et al. Machine learning facilitates hotspot classification in PSMA-PET/CT with nuclear medicine specialist accuracy. Diagnostics (Basel). 2020;10(9):622. doi: 10.3390/diagnostics10090622
   PubMedGoogle Scholar
• Yi Z, Hu S, Lin X, et al. Machine learning-based prediction of invisible intraprostatic prostate cancer lesions on 68Ga-PSMA-11 PET/CT in patients with primary prostate cancer. Eur J Nucl Med Mol Imaging. 2022;49(5):1523–1534. doi: 10.1007/s00259-021-05631-6
   PubMed Web of Science ®Google Scholar
• Ghezzo S, Mongardi S, Bezzi C, et al. External validation of a convolutional neural network for the automatic segmentation of intraprostatic tumor lesions on 68Ga-PSMA PET images. Front Med. 2023;10. doi: 10.3389/fmed.2023.1133269
   Web of Science ®Google Scholar
• Kostyszyn D. Prostate GTV Segmentation. GitLab. 2020. Available from: https://gitlab.com/dejankostyszyn/prostate-gtv-segmentation
   Google Scholar
• Nickols N, Anand A, Johnsson K, et al. aPROMISE: a novel automated PROMISE platform to standardize evaluation of tumor burden in 18F-DCFPyL images of veterans with prostate cancer. J Nucl Med. 2022;63(2):233–239. doi: 10.2967/jnumed.120.261863
   PubMed Web of Science ®Google Scholar
• PYLARIFY AI™ enables accurate, efficient, and reproducible quantification of PYLARIFY® PET/CT scans [Internet]. [cited 2024 Mar 7]. Available from: https://www.pylarify.com/ai
   Google Scholar
• Benyon B. FDA’s approval of pluvicto gives some patients with prostate cancer a ‘truly targeted therapy’ with modest side effects. 2022 [cited 2024 Jul 14]. Available from: https://www.curetoday.com/view/fda-s-approval-of-pluvicto-gives-some-patients-with-prostate-cancer-a-truly-targeted-therapy-with-modest-side-effects#
   Google Scholar
• Bois F, Noirot C, Dietemann S, et al. [68Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review. Am J Nucl Med Mol Imaging. 2020;10(6):349–374.
   PubMed Web of Science ®Google Scholar
• Illuccix® Granted Transitional Pass-Through Payment Status [Internet]. [cited 2024 Mar 7]. Available from: https://www.prnewswire.com/news-releases/illuccix-granted-transitional-pass-through-payment-status-301557686.html
   Google Scholar
• Wahl RL, Sunderland J. Advocating for expanded access. J Nucl Med. 2021;62(11):1S–2S. doi: 10.2967/jnumed.121.263273
   PubMedGoogle Scholar
• Radiopharmaceutical Unbundling Included in CMS FY25 HOPPS Proposed Rule [Internet]. [cited 2024 Jul 14]. Available from: https://snmmi.org/Web/News/Articles/Radiopharmaceutical-Unbundling-Included-in-CMS-FY25-Proposed-Rule-on-Hospital-Outpatient-Prospective.aspx
   Google Scholar
• Highlights of Prescribing Information for Pluvicto. [Internet]. [cited 2024 Mar 7]. Available from: https://www.novartis.com/us-en/sites/novartis_us/files/pluvicto.pdf
   Google Scholar
• Sartor OA, Morris MM, Chi KN, et al. PSMAfore: A phase 3 study to compare 177Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2022;40(6_suppl):TPS211–TPS211. doi: 10.1200/JCO.2022.40.6_suppl.TPS211
   Google Scholar
• Novartis Pluvicto™ shows clinically meaningful and highly statistically significant rPFS benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer in the pre-taxane setting [Internet]. [cited 7 Mar 2024]. Available from: https://www.novartis.com/news/media-releases/novartis-pluvictotm-shows-clinically-meaningful-and-highly-statistically-significant-rpfs-benefit-patients-psma-positive-metastatic-castration-resistant-prostate-cancer-pre-taxane-setting
   Google Scholar
• Novartis confirms plans to file for Pluvicto® pre-taxane label expansion in H2 2024 based on latest data from Phase III PSMAfore study [Internet]. [cited 2024 Jul 14]. Available from: https://www.novartis.com/news/novartis-confirms-plans-file-pluvicto-pre-taxane-label-expansion-h2-2024-based-latest-data-from-phase-iii-psmafore-study
   Google Scholar
• Jang A, Kendi AT, Sartor O. Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials. Ther Adv Med Oncol. 2023;15:17588359231157632. doi:10.1177/17588359231157632
   Web of Science ®Google Scholar
• Kratochwil C, Fendler WP, Eiber M, et al. Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2023;50(9):2830–2845. doi: 10.1007/s00259-023-06255-8
   PubMed Web of Science ®Google Scholar
• Lilly Completes Acquisition of POINT Biopharma [Internet]. [cited 2024 Mar 7]. Available from: https://investor.lilly.com/news-releases/news-release-details/lilly-completes-acquisition-point-biopharma
   Google Scholar
• Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio [Internet]. [cited 2024 Mar 7]. Available from: https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Adds-Premier-Radiopharmaceutical-Platform-with-Acquisition-of-RayzeBio/default.aspx
   Google Scholar
• Wahl RL, Sunderland J. Advancing Radiopharmaceutical Therapy. J Nucl Med. 2021;62(2):1S–2S. doi: 10.2967/jnumed.121.263273
   PubMed Web of Science ®Google Scholar